{
  "id": 16019871,
  "title": "Galderma Q3 Sales Climb; Confirms FY26 Core EBITDA Margin View, Lifts Sales Growth Outlook; Stock Up",
  "url": "https://urgent.news/2026/10/22/galderma-q3-sales-climb-confirms-fy26-core-ebitda-margin-view-lifts",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-22T07:27:20.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/galderma-q3-sales-climb-confirms-fy26-core-ebitda-margin-view-lifts-sales-growth-outlook"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, reported Thursday strong growth in third-quarter sales, with broad-based double-digit growth across geographies and product categories.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}